According to a new research report “IgA Nephropathy Pipeline Analysis, 2017 – Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, IgA nephropathy currently exhibits a pipeline with 12 drug candidates.
IgA nephropathy pipeline offers novel therapeutic targets for the treatment of IgA nephropathy
The study analyzed that the IgA nephropathy pipeline comprises of 12 drug candidates, of which one drug candidate is in Phase III stage, five drug candidates are in Phase II stage and three drug candidates are in Pre-Clinical stage. Also, there are two inactive drug candidates and one discontinued drug candidate. IgA nephropathy, also known as Berger’s disease, is a kidney disorder that occurs when IgA antibody gets settled in the kidneys. This leads to inflammation that with time hinders the kidney’s ability to filter wastes from blood. IgA nephropathy is a silent disease in its early stages with no symptoms. But the most common symptoms that are usually observed are proteinuria and hematuria. IgA nephropathy does not have a specific treatment, and the only treatment available is to delay or prevent end stage renal disease (ESRD). Therefore, combination therapies are being used to slow down the rate of proteinuria and hematuria and the use of various targets including a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS) is expected to provide an effective and concrete treatment for the disease, with latest technological advancements further adding to the pipeline growth.
Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis
Insights on pipeline segments
As per the findings of the research, around 33.0% of drug candidates of IgA nephropathy pipeline are being developed to be administered by subcutaneous route and 22.0% are being developed to be administered by oral route. Route of administration of around 45.0% drug candidates of IgA nephropathy pipeline is not disclosed.
Many companies are involved in the development of IgA nephropathy pipeline, with their products in different phases. Mallinckrodt plc has its drug candidate in Phase III stage of development. Merck KGaA, Pharmalink AB, Anthera Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc. and Omeros Corporation each have their drug candidates in Phase II stage of development.
TARGIT drug delivery technology platform for IgA nephropathy drug development
Pharmalink AB is using TARGIT drug delivery technology platform for the development of Budesonide for IgA nephropathy. The TARGIT technology is based on the application of a combination of enteric polymers onto injection-moulded starch capsules, for the targeted delivery of drugs to specific regions of the large intestine. The TARGIT capsule can accommodate relatively large doses of drug and can be filled with a wide range of formulations such as powders, granules, tablets, mini-tablets, coated pellets or semisolids.
Phase III – Highest stage of development for IgA nephropathy
There is one IgA nephropathy drug candidate in the Phase III stage of development. Seractide acetate is a Phase III stage drug candidate being developed by Mallinckrodt plc for the treatment of IgA nephropathy. It is a peptide that reduces remission of proteinuria. The drug candidate is administered by subcutaneous route.
Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis/report-sample
Major companies collaborate for the development of IgA nephropathy Pipeline
The research finds that different companies have collaborated for the development of IgA nephropathy pipeline. In October 2012, Pharmalink AB entered into a contract with Patheon Inc. for manufacturing of Nefecon. The contract includes the manufacturing of Nefecon and no commercial terms were disclosed. In December 2011, Pharmalink AB gained an exclusive global license to Archimedes Pharma Ltd. for TARGIT drug delivery technology platform for use in Nefecon.
Some of the key players developing drugs for IgA nephropathy include Mallinckrodt plc, Merck KGaA, Anthera Pharmaceuticals, Inc., Pharmalink AB, Rigel Pharmaceuticals, Inc., Omeros Corporation, IGAN Biosciences, Inc., Shire plc and Visterra, Inc.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Company Name: P&S Market Research
Contact Person: Abhishek
Address:347 5th Ave. #1402- 210
City: New York City
State: New York
Country: United States